<VariationArchive RecordType="classified" VariationID="831267" VariationName="NC_000019.10:g.(?_45584613)_(45584774_?)del" VariationType="Deletion" Accession="VCV000831267" Version="5" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-11-11" DateCreated="2020-04-15" MostRecentSubmission="2023-11-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="821265" VariationID="831267">
      <GeneList>
        <Gene Symbol="OPA3" FullName="outer mitochondrial membrane lipid metabolism regulator OPA3" GeneID="80207" HGNC_ID="HGNC:8142" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19q13.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="45527427" stop="45584802" display_start="45527427" display_stop="45584802" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="46031024" stop="46088121" display_start="46031024" display_stop="46088121" Strand="-" />
          </Location>
          <OMIM>606580</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000019.10:g.(?_45584613)_(45584774_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19q13.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" innerStart="46087871" innerStop="46088032" display_start="46087871" display_stop="46088032" variantLength="162" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.(?_46087871)_(46088032_?)del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.(?_46087871)_(46088032_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000019.10:g.(?_45584613)_(45584774_?)del AND multiple conditions" Accession="RCV001031836" Version="5">
        <ClassifiedConditionList TraitSetID="9677">
          <ClassifiedCondition DB="MedGen" ID="C0574084">3-Methylglutaconic aciduria type 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1833809">Optic atrophy 3</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-04-06" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2023-11-11">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11668429</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25201222</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9677" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">3-alpha methylglutaconic aciduria type III</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MGA type III</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Optic atrophy infantile with chorea and spastic paraplegia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Iraqi Jewish optic atrophy plus</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Costeff optic atrophy syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">3-Methylglutaconic aciduria type 3</ElementValue>
                <XRef ID="3-Methylglutaconic+Aciduria+Type+III/34" DB="Genetic Alliance" />
                <XRef ID="297232009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">OPA3, AUTOSOMAL RECESSIVE</ElementValue>
                <XRef Type="MIM" ID="258501" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">OPTIC ATROPHY 3, AUTOSOMAL RECESSIVE</ElementValue>
                <XRef Type="MIM" ID="258501" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">3-methylglutaconic aciduria type III</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">OPA3-Related 3-Methylglutaconic Aciduria</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MGCA3</ElementValue>
                <XRef Type="MIM" ID="258501" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MGA3</ElementValue>
                <XRef Type="MIM" ID="258501" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">OPA3</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Costeff syndrome is characterized by optic atrophy and/or choreoathetoid movement disorder with onset before age ten years. Optic atrophy is associated with progressive decrease in visual acuity within the first years of life, sometimes associated with infantile-onset horizontal nystagmus. Most individuals have chorea, often severe enough to restrict ambulation. Some are confined to a wheelchair from an early age. Although most individuals develop spastic paraparesis, mild ataxia, and occasional mild cognitive deficit in their second decade, the course of the disease is relatively stable.</Attribute>
                <XRef ID="NBK1473" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5663" />
                <XRef ID="5663" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301646</ID>
                <ID Source="BookShelf">NBK1473</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C5-OH Acylcarnitine, Organic Acidemias, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH-Elevated.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Organic Acidemias: Elevated C5-OH, 2022</CitationText>
              </Citation>
              <XRef ID="67047" DB="Orphanet" />
              <XRef ID="C0574084" DB="MedGen" />
              <XRef ID="MONDO:0009787" DB="MONDO" />
              <XRef Type="MIM" ID="258501" DB="OMIM" />
            </Trait>
            <Trait ID="5680" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">OPTIC ATROPHY 3, AUTOSOMAL DOMINANT</ElementValue>
                <XRef Type="MIM" ID="165300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Optic atrophy and cataract, autosomal dominant</ElementValue>
                <XRef ID="Optic+atrophy+and+cataract%2C+autosomal+dominant/5385" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Optic atrophy, cataract, and neurologic disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Optic atrophy 3</ElementValue>
                <XRef ID="MONDO:0008133" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">OPA3</ElementValue>
                <XRef Type="MIM" ID="165300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10203" />
                <XRef ID="10203" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="67036" DB="Orphanet" />
              <XRef ID="C1833809" DB="MedGen" />
              <XRef ID="MONDO:0008133" DB="MONDO" />
              <XRef Type="MIM" ID="165300" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2356397" SubmissionDate="2023-02-03" DateLastUpdated="2023-11-11" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="NM_025136.3_Deletion (Exon 1)|MedGen:C0574084;C1833809" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001195143" DateUpdated="2023-11-11" DateCreated="2020-04-15" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11668429</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25201222</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 1 of the OPA3 gene, which includes the initiator codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in OPA3 are known to be pathogenic (PMID: 11668429, 25201222). This variant has not been reported in the literature in individuals affected with OPA3-related conditions. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="OPA3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.(?_46087871)_(46088032_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0574084" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1833809" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2356397" TraitType="Disease" MappingType="XRef" MappingValue="C0574084" MappingRef="MedGen">
        <MedGen CUI="C0574084" Name="3-Methylglutaconic aciduria type 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2356397" TraitType="Disease" MappingType="XRef" MappingValue="C1833809" MappingRef="MedGen">
        <MedGen CUI="C1833809" Name="Optic atrophy 3" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

